Cover Image
市場調查報告書

不孕症的全球市場

Global Infertility Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 324718
出版日期 內容資訊 英文 92 Pages
訂單完成後即時交付
價格
Back to Top
不孕症的全球市場 Global Infertility Market 2015-2019
出版日期: 2015年02月18日 內容資訊: 英文 92 Pages
簡介

診斷不孕症的原因很困難,不過許多可治療。治療的選項,根據基礎疾病而不相同。全球不孕症市場,2014年∼2019年預計以4.52%的年複合成長率成長。

本報告提供全球不孕症市場相關調查分析、市場規模與成長率、市場趨勢、市場的推動要素與課題、市場機會驗證、主要供應商等相關的系統性資訊。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 疾病概要

  • 病因
  • 徵兆與症狀
  • 治療
  • 檢驗和診斷

第7章 國家概要

  • 美國
  • 英國

第8章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第9章 市場區隔:各類型

  • 全球不孕症治療藥市場
    • 市場規模與預測
  • 全球不孕症治療設備市場
    • 市場規模與預測

第10章 市場區隔:各根本原因

第11章 地區區分

  • 南北美洲的不孕症市場
    • 市場規模與預測
  • 亞太地區的不孕症市場
    • 市場規模與預測
  • 歐洲、中東、非洲地區的不孕症市場
    • 市場規模與預測

第12章 購買標準

第13章 推動市場成長要素

第14章 成長推動因素與其影響

第15章 市場課題

第16章 成長推動因素與課題的影響

第17章 市場趨勢

第18章 趨勢與其影響

第19章 業者情勢

  • 競爭模式
  • 市場佔有率分析
  • 其他卓越供應商

第20章 主要供應商分析

  • Bayer HealthCare
  • CooperSurgical
  • Ferring Pharmaceuticals
  • Merck & Co. Inc.

第21章 相關報告

圖表

目錄
Product Code: IRTNTR5289

About Infertility

Infertility is a widespread problem, and it is the inability to conceive after having regular unprotected sex. In one-third of the cases, infertility is because of either female infertility factors or male infertility factors. In rest of the cases, the cause is either unknown or a combination of both male and female factors. In males, infertility is due to a couple of factors including low sperm production, abnormal sperm function, or blockages that prevent the delivery of sperm. The cause of infertility can be difficult to diagnose, but many treatments are available. Treatment options depend on underlying problems.

TechNavio's analysts forecast the Global Infertility market to grow at a CAGR of 4.52 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Infertility market for the period 2015-2019. The Global Infertility market can be divided into two segments: Infertility Drugs and Infertility Devices. To calculate the market size, the report considers revenue generated from the sales of various drugs and devices used in the treatment of infertility.

TechNavio's report, the Global Infertility Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Infertility market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Bayer Healthcare
  • CooperSurgical
  • Ferring Pharmaceuticals
  • Merck & Co.

Other Prominent Vendors

  • Abbott Laboratories
  • AbbVie
  • Actavis
  • Apricus Biosciences
  • AstraZeneca
  • Bristol-Myers Squibb
  • Dong-A Socio
  • Elelixis Diagnostics
  • Eli Lily
  • Halotech DNA
  • HRA Pharma
  • Invo Bioscience
  • Medical Electronic Systems
  • Novartis
  • Pfizer
  • PregLem
  • Sanofi
  • Vivus

Market Driver

  • Increase in Aging Population
  • For a full, detailed list, view our report

Market Challenge

  • Patent Expires of Major Blockbuster Drugs
  • For a full, detailed list, view our report

Market Trend

  • Increase in Awareness
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Disease Overview

  • 06.1. Etiology
    • 06.1.1. Male Infertility Etiology
    • 06.1.2. Pre-testicular
    • 06.1.3. Testicular
    • 06.1.4. Post-testicular
    • 06.1.5. Others
    • 06.1.6. Female Infertility Etiology
    • 06.1.7. Female Infertility associated with Anovulation
    • 06.1.8. Female Infertility of Tubal Origin
    • 06.1.9. Female Infertility of Uterine Origin
    • 06.1.10. Female Infertility of Other Origin
    • 06.1.11. Female Infertility, Unspecified
  • 06.2. Signs and Symptoms
    • 06.2.1. Male Infertility Signs and Symptoms
    • 06.2.2. Female Infertility Signs and Symptoms
  • 06.3. Treatment
    • 06.3.1. Treatment for Male Infertility
    • 06.3.2. Treatment for Female Infertility
    • 06.3.3. Reproductive Assistance
  • 06.4. Tests and Diagnosis
    • 06.4.1. Male: Tests and Diagnosis
    • 06.4.2. Female: Tests and Diagnosis
    • 06.4.3. Prevalence

07. Country Overview

    • 07.1.1. US
    • 07.1.2. UK

08. Market Landscape

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast
  • 08.3. Five Forces Analysis

09. Market Segmentation by Type

    • 09.1.1. Infertility Drugs
    • 09.1.2. Infertility Devices
  • 09.2. Global Infertility Drugs Market
    • 09.2.1. Market Size and Forecast
  • 09.3. Global Infertility Devices Market
    • 09.3.1. Market Size and Forecast

10. Market Segmentation by Underlying Cause

11. Geographical Segmentation

  • 11.1. Infertility Market in Americas
    • 11.1.1. Market Size and Forecast
  • 11.2. Infertility Market in APAC Region
    • 11.2.1. Market Size and Forecast
  • 11.3. Infertility Market in EMEA Region
    • 11.3.1. Market Size and Forecast

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

  • 19.1. Competitive Scenario
    • 19.1.1. Key News
    • 19.1.2. Licensing and Collaborations
    • 19.1.3. Mergers and Acquisitions
  • 19.2. Market Share Analysis 2014
  • 19.3. Other Prominent Vendors

20. Key Vendor Analysis

  • 20.1. Bayer HealthCare
    • 20.1.1. Key Facts
    • 20.1.2. Business Overview
    • 20.1.3. Business Segmentation by Revenue 2013
    • 20.1.4. Business Segmentation by Revenue 2012 and 2013
    • 20.1.5. Geographical Segmentation by Revenue 2013
    • 20.1.6. Business Strategy
    • 20.1.7. Recent Developments
    • 20.1.8. SWOT Analysis
  • 20.2. CooperSurgical
    • 20.2.1. Key Facts
    • 20.2.2. Business Description
    • 20.2.3. Business Segmentation
    • 20.2.4. Business Segmentation by Revenue
    • 20.2.5. Business Segmentation by Revenue 2012 and 2013
    • 20.2.6. Business Strategy
    • 20.2.7. Key Developments
    • 20.2.8. SWOT Analysis
  • 20.3. Ferring Pharmaceuticals
    • 20.3.1. Key Facts
    • 20.3.2. Business Overview
    • 20.3.3. SWOT Analysis
  • 20.4. Merck & Co. Inc.
    • 20.4.1. Key Facts
    • 20.4.2. Business Overview
    • 20.4.3. Business Segmentation by Revenue 2013
    • 20.4.4. Business Segmentation by Revenue 2012 and 2013
    • 20.4.5. Sales by Geography
    • 20.4.6. Business Strategy
    • 20.4.7. Key Developments
    • 20.4.8. SWOT Analysis

21. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Etiology of Male Infertility
  • Exhibit 3: Etiology of Female Infertility
  • Exhibit 4: Treatment of Male Infertility
  • Exhibit 5: Diagnosis of Male Infertility
  • Exhibit 6: Factors Affecting Infertility in 2014 (Global)
  • Exhibit 7: Percentage of Primary and Secondary Infertility in 2010 (Global)
  • Exhibit 8: Percentage of Married Infertile Women with Primary Infertility: US, 1965-2010
  • Exhibit 9: Causes of Infertility in US
  • Exhibit 10: Increasing Prevalence of Infertility of Women (various age-groups in year) in UK 2009
  • Exhibit 11: Causes of Infertility in UK 2009
  • Exhibit 12: Global Infertility Market 2014-2019 (US$ million)
  • Exhibit 13: Segmentation of Global Infertility Market by Type
  • Exhibit 14: Global Infertility Drugs Market 2014-2019 (US$ million)
  • Exhibit 15: Global Infertility Devices Market 2014-2019 (US$ million)
  • Exhibit 16: Global infertility market by drugs & devices in 2014 and 2019 (US$ million)
  • Exhibit 17: Global Infertility Market Segmentation by Type 2014
  • Exhibit 18: Global Infertility Market Segmentation by Type 2019
  • Exhibit 19: Global Infertility Market 2014-2019 (US$ million)
  • Exhibit 20: Segmentation of Global Infertility Market by Underlying Cause
  • Exhibit 21: Global Infertility Market by Geographical Segmentation 2014
  • Exhibit 22: Infertility Market in Americas 2014-2019 (US$ million)
  • Exhibit 23: Infertility Market in APAC region 2014-2019 (US$ million)
  • Exhibit 24: Infertility Market in EMEA Region 2014-2019 (US$ million)
  • Exhibit 25: Global infertility market by region in 2014 and 2019 (US$ million)
  • Exhibit 26: CooperSurgical: YoY Sales Comparison 2010-2013 (US$ million)
  • Exhibit 27: Merck's Gonal-f YoY Sales Comparison 2011-2013 (US$ million)
  • Exhibit 28: Bayer HealthCare: Business Segmentation by Revenue 2013
  • Exhibit 29: Bayer HealthCare: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 30: Bayer HealthCare: Geographical Segmentation by Revenue 2013
  • Exhibit 31: CooperSurgical: Business Segmentation 2013
  • Exhibit 32: CooperSurgical: Business Segmentation by Revenue 2013
  • Exhibit 33: CooperSurgical: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 34: Merck & Co. Inc.: Business Segmentation by Revenue 2013
  • Exhibit 35: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 36: Merck & Co. Inc.: Sales by Geography 2013
Back to Top